The initial public offerings of Hy Tech Engineers, Skyways Air Services, and Symbiotec Pharmalab closed on Thursday, recording strong subscription levels across categories. Hy Tech Engineers led the offerings with a 244.41-times subscription, while both Skyways Air Services and Symbiotec Pharmalab were subscribed over 71 times. Shares are proposed to be listed on the BSE and NSE on September 1.

The initial public offerings (IPOs) of Hy Tech Engineers, Symbiotec Pharmalab, and Skyways Air Services closed on Thursday, attracting substantial demand from investors across various categories.

Hy Tech Engineers led the offerings with an overall subscription of 244.41 times. The qualified institutional buyer (QIB) portion was booked 255.77 times, the non-institutional investor (NII) portion saw a 402.29-times subscription, and the retail portion was booked 170.58 times. The Maharashtra-based company's ₹135.73-crore IPO had a price band fixed at ₹50-53 per equity share. The company revised its IPO size prior to closure by trimming the fresh issue to ₹60 crore from ₹70 crore, while increasing the offer-for-sale (OFS) component to nearly 1.43 crore shares from 1.19 crore shares.

Hy Tech Engineers has proposed to utilize ₹29.96 crore from the net proceeds to procure machinery and equipment for expansion at its Kavathe Unit, Shirwal Unit, and Pithampur Unit-I. Additionally, ₹16 crore will be allocated toward the repayment of loans, with the remaining amount designated for general corporate purposes.

Skyways Air Services closed its issue with a 71.25-times subscription and raised ₹174.5 crore from anchor investors. The IPO comprised a fresh issue of up to 2.89 crore shares and an OFS of up to 1.33 crore shares by promoters and existing shareholders. The price band was fixed at ₹131-138 per share. Incorporated in 1984, Skyways Air Services operates in air and ocean freight forwarding, trucking, warehousing, customs broking, and express cargo and parcel delivery. The company stated that proceeds from the fresh issue will be used for the repayment or prepayment of borrowings, funding incremental working capital requirements, and general corporate purposes.

Symbiotec Pharmalab recorded a 71.26-times subscription on the final day of bidding. The Indore-based research and development-driven pharmaceutical and biotechnology company mobilised ₹526 crore from anchor investors. Its IPO comprised a fresh issue of shares worth up to ₹150 crore and an OFS component amounting to ₹1,607 crore, with a price band fixed at ₹938-988 per equity share, valuing the company at around ₹6,350 crore at the upper limit. As part of the OFS, promoter Satwani Holdings LLP, along with investors Rosewood Investments and India Business Excellence Fund III, offloaded shares. Proceeds from the fresh issue are earmarked for debt payment and general corporate purposes.

Shares for all three companies are proposed to be listed on both the BSE and the NSE on September 1.

"The robust subscription numbers across Hy Tech Engineers, Skyways Air Services, and Symbiotec Pharmalab highlight sustained investor appetite in the primary market. With high participation across retail, NII, and QIB categories—particularly seen in Hy Tech Engineers' 244x subscription—companies are leveraging public markets effectively for debt reduction, capacity expansion, and working capital needs. The upcoming listings on September 1 will provide a clear indicator of secondary market sentiment for these sectors." — Dr. Shishir Gupta, Founder & CEO, StartupLanes

Recent StartupLanes Articles

Browse through our 30 latest publications on venture capital, startups, and angel investing.

Indian Listed AI Market Could Add Up to $100 Billion From Upcoming IPOs: Goldman Sachs Oct 22, 2026
Netflix Records Highest Paid Subscriber Net Additions in India for Q3 Oct 22, 2026
Kalpataru Projects International Secures New Orders Worth ₹2,349 Crore Oct 22, 2026
MCX Copper Futures Decline From Recent Highs as Market Approaches Key Support Levels Oct 22, 2026
OpenAI Acquires Orchestra Bio to Expand Life Sciences and Drug Development Capabilities Oct 22, 2026
Dr. Reddy’s Laboratories Receives DCGI Approval for Toripalimab in India Oct 22, 2026
Anthropic's Confidential IPO Filing Reveals $80.7 Billion H1 Loss and Heavy Computing Costs Oct 22, 2026
Jio Platforms Launches ₹30,213 Crore IPO: Key Details, Valuations, and Brokerage Views Oct 22, 2026
State Bank of India Reports Suspected Customer Data Exposure on Dark Web Oct 22, 2026
US Secretary of State Marco Rubio Terms Envoy Meeting with Ukrainian President Positive Oct 22, 2026
Rupee Strengthens 29 Paise Against US Dollar in Early Trade, Supported by RBI and Jio IPO Inflows Oct 22, 2026
Brent Crude Stays Above $110 Amid West Asia Supply Concerns and Inventory Data Oct 22, 2026
Indian Market Updates: Corporate Earnings, Strategic Agreements, and Expansion Plans Across Sectors Oct 22, 2026
Corporate Updates: Infosys Expands Truist Collaboration, Cemindia Raises ₹1,400 Crore via QIP, and Multiple Firms Report Contracts and Acquisitions Oct 22, 2026
Centre to Review National Mineral Policy 2019 to Focus on Critical Minerals and Deep-Sea Resources Oct 22, 2026